Multispecific antibodies are rising stars in the field of antibody therapeutics, offering better specificity, targeting ability, and therapeutic effects than traditional monoclonal antibodies.
Multiple Targets, Infinite Possibilities
Multiple Targets, Infinite Possibilities
Multispecific antibodies are rising stars in the field of antibody therapeutics, offering better specificity, targeting ability, and therapeutic effects than traditional monoclonal antibodies.
Multispecific antibodies are rising stars in the field of antibody therapeutics, offering better specificity, targeting ability, and therapeutic effects than traditional monoclonal antibodies.
Tobias R. Kollmann, Arnaud Marchant, and Sing Sing Way | Nov 14, 2022 | 3 min read
Pregnancy-induced changes in the immune system are key to a successful birth. Understanding those changes could allow researchers to protect both mother and child.
The Scientist’s Creative Services Team | 2 min read
An expert panel will discuss the interplay between cancer and the immune system, and how researchers develop immunotherapies and other immune-supporting strategies against cancer.
A vaccine strategy involving formulation changes, an initial escalating dose, and a longer wait for booster immunization results in more-effective antibody production against HIV in rhesus monkeys, a study finds.
BA.2.75 is spreading rampantly in India and has so far reached at least 20 other countries, but it doesn’t seem to be outcompeting other Omicron SARS-CoV-2 subvariants.
Studies show that a fourth mRNA vaccine dose offers the elderly and other high-risk groups strong protection against hospitalization and death from COVID-19, but experts say benefits for other populations may be more limited.
The Scientist’s Creative Services Team and Refeyn | 3 min read
Mass photometry is an interferometric scattering-based technique offering researchers unprecedented characterization of biomolecular complexes and oligomerization in physiologically-relevant situations.
Unlike studies of antibody-rich transfusions in hospitalized patients, which overall have not found clear benefits, a new randomized trial finds that early convalescent plasma treatment cuts hospitalizations in half.